Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $40.7 million.

  • Barinthus Biotherapeutics' Shares Outstanding (Weighted Average) rose 314.99% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year increase of 314.99%. This contributed to the annual value of $39.3 million for FY2024, which is 250.54% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Shares Outstanding (Weighted Average) stood at $40.7 million, which was up 314.99% from $40.3 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $40.7 million for Q3 2025, and its period low was $8.1 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $38.5 million (2023), whereas its average is $36.0 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 21496.74% in 2021, then soared by 164.93% in 2024.
  • Barinthus Biotherapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $24.9 million in 2021, then skyrocketed by 49.6% to $37.2 million in 2022, then grew by 3.06% to $38.4 million in 2023, then rose by 2.51% to $39.3 million in 2024, then rose by 3.34% to $40.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $40.7 million for Q3 2025, versus $40.3 million for Q2 2025 and $40.3 million for Q1 2025.